Show simple item record

dc.contributor.authorLoi, S
dc.date.accessioned2021-02-04T01:31:31Z
dc.date.available2021-02-04T01:31:31Z
dc.date.issued2013-07-01
dc.identifierpii: 2013ONCOIMM0071
dc.identifier.citationLoi, S. (2013). Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. ONCOIMMUNOLOGY, 2 (7), https://doi.org/10.4161/onci.24720.
dc.identifier.issn2162-4011
dc.identifier.urihttp://hdl.handle.net/11343/259391
dc.description.abstractBy analyzing over 2000 samples from a randomized clinical trial, we have recently associated high levels of tumor-infiltrating lymphocytes with an excellent prognosis among triple negative breast cancer patients as well with improved clinical responses to immunogenic chemotherapy among patients bearing HER2 over-expression. These findings suggest that immunomodulation could represent a new approach to treat these aggressive breast cancer subtypes.
dc.languageEnglish
dc.publisherLANDES BIOSCIENCE
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleTumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
dc.typeJournal Article
dc.identifier.doi10.4161/onci.24720
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleOncoImmunology
melbourne.source.volume2
melbourne.source.issue7
dc.rights.licenseCC BY-NC
melbourne.elementsid1070725
melbourne.contributor.authorLoi, Sherene
dc.identifier.eissn2162-402X
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record